A 2023 Australian survey found that cannabis users frequently report dual medical-recreational motives rather than distinct categories. This cross-sectional analysis of 3,042 adults reveals that australian medical cannabis use patterns are more nuanced than regulatory frameworks suggest, with important implications for clinical practice and patient counseling.
Cannabis modalities matter for momentary subjective drug effects.
A new ecological momentary assessment study reveals that cannabis consumption method subjective effects vary significantly between delivery mechanisms. Researchers found vaporizers produced less subjective intoxication while bongs were associated with greater positive effects compared to other methods in young recreational users.
Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis.
A real-time smartphone-based study of 258 MS patients revealed that higher pain levels drive increased cannabis use and decreased alcohol consumption. This research using ecological momentary assessment provides clinical evidence that MS patients make deliberate, symptom-driven substance use decisions throughout their daily lives.
Prenylated apigenin derivatives from Cannabis sativa L.: isolation, biosynthesis, and anti-inflammatory properties.
Laboratory research has identified prenylated apigenin derivatives from Cannabis sativa with anti-inflammatory properties, representing novel non-psychotropic compounds beyond traditional cannabinoids. While these prenylated apigenin cannabis anti-inflammatory properties show promise in early studies, clinical validation remains necessary. This research expands our understanding of cannabis chemistry and potential therapeutic applications.
Cannabis and Mental Health: A Review.
A comprehensive JAMA review reveals the stark gap between widespread cannabis use for mental health conditions and actual clinical evidence. While patients commonly self-medicate with cannabis for psychiatric symptoms, this systematic analysis found insufficient evidence supporting cannabis mental health benefits, with documented risks particularly from THC-predominant products.
Medicinal plants in the management of muscle loss and sarcopenia: A narrative review of preclinical and clinical evidence from eight species.
A 2024 narrative review identifies cannabis muscle health applications alongside seven other medicinal plants for sarcopenia management. While this academic inclusion validates cannabis research interest, clinical applications await controlled trial evidence with standardized preparations and defined protocols.
Pilot study on cannabis-induced alterations in platelet function: implications for transfusion medicine.
A pilot study reveals cannabis extracts can alter platelet function in laboratory settings, raising questions about cannabis effects on platelet function and transfusion safety. While preliminary, this research highlights the need for further investigation into how cannabis use might impact blood donation and platelet product quality.
Quasi-randomization to Cannabinoid Condition in Studies of US Legal Market Cannabis: Characteristics of Accepters Versus Decliners of Condition Assignment.
A methodology study examining cannabis research selection bias found systematic differences between participants who accept versus decline assigned cannabis conditions. This quasi-randomization research provides crucial insights for interpreting legal market cannabis studies where traditional randomization is prohibited by federal regulations.
Regular cannabinoid use and inflammatory biomarkers: Systematic review and hierarchical meta-analysis.
A comprehensive systematic review of cannabis inflammatory biomarkers found associations with anti-inflammatory markers in observational studies. However, the clinical significance of these laboratory changes remains uncertain, and the predominance of observational data limits causal conclusions about cannabis as an anti-inflammatory intervention.
Discrepancies between subjective and objective cognition in persons with multiple sclerosis: Exploring the role of cannabis use.
Research examining cannabis cognitive effects in multiple sclerosis patients found that cannabis users report greater perceived cognitive deficits than non-users. This cross-sectional study of 847 MS patients provides important insights into the perception-reality gap regarding cannabis and cognition in neurological disease management.